Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
688505
Company Profile
Business description
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. Geographically, it derives revenue from Mainland China.
Contact
308 Cailun Road
Zhangjiang Hi-Tech Park
Pudong
Shanghai201210
CHNT: +86 2158953355
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
899
Stocks News & Analysis
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
Microsoft’s earnings report is expected to touch on AI adoption and monetization.
stocks
World’s largest miner overvalued after solid quarter
The ongoing war is likely to keep commodity prices even more volatile than usual until it is resolved.
stocks
Hidden value in an expensive ASX
How investors can uncover value beyond the index heavyweights.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,003.30 | 48.10 | -0.53% |
| CAC 40 | 8,156.43 | 79.28 | -0.96% |
| DAX 40 | 24,194.90 | 75.97 | -0.31% |
| Dow JONES (US) | 49,490.03 | 340.65 | 0.69% |
| FTSE 100 | 10,476.46 | 21.63 | -0.21% |
| HKSE | 25,929.45 | 233.79 | -0.89% |
| NASDAQ | 24,657.57 | 397.60 | 1.64% |
| Nikkei 225 | 58,952.11 | 633.75 | -1.06% |
| NZX 50 Index | 12,908.15 | 37.45 | -0.29% |
| S&P 500 | 7,137.90 | 73.89 | 1.05% |
| S&P/ASX 200 | 8,768.00 | 51.50 | -0.58% |
| SSE Composite Index | 4,096.41 | 9.85 | -0.24% |